ACP3 and prostate carcinoma: Indeed, one such vaccine, Provenge, has entered the market for the routine treatment of prostate cancer and involves the co-culture of moDCs obtained by leukapheresis, with the TSA, prostatic acid phosphatase (PAP), to which T-cell responses have been detected following their reinfusion into patients (28).